Optum, Eden Prairie, MN, USA.
Merck and Co. Inc., Kenilworth, NJ, USA.
Curr Med Res Opin. 2022 Aug;38(8):1443-1450. doi: 10.1080/03007995.2022.2088714. Epub 2022 Jul 21.
OBJECTIVE: To describe the burden of comorbid conditions and comedications among people living with HIV (PLWH) vs. people living without HIV (PLWoH). METHODS: This was a case-control study conducted among insured patients using administrative claims data. Adult PLWH were identified by antiretroviral therapy (ART) claims or HIV/AIDS diagnosis codes from 1 January 2018 to 31 December 2018 (index date was set by the earliest claim). Continuous enrollment was required for ≥12 months pre-index (baseline) and ≥30 days post-index (follow-up). Patients were required to have ≥1 HIV diagnosis during baseline or follow-up. Those with only HIV prophylaxis were excluded. PLWoH were matched 2:1 to PLWH on demographic characteristics. Study outcomes were compared using -tests with robust standard errors in an ordinary least squares regression or Rao-Scott tests. RESULTS: The study included 20,256 PLWH and 40,512 matched PLWoH, mean age 52 years. PLWH vs. PLWoH had higher mean (SD) Charlson comorbidity index scores (0.93 [1.59] vs. 0.61 [1.28]; < .001) and a greater proportion had ≥1 comorbidity (69.1% vs. 54.5%, < .001). The most prevalent comorbidities included hypertension (33.9% vs. 32.2%; < .001), hyperlipidemia (29.4% vs. 24.6%; < .001), chronic kidney disease (13.6% vs. 9.4%, < .001), depression (13.1% vs. 7.3%, < .001) and substance abuse (12.8% vs. 7.1%, < .001). Mean (SD) non-ART prescription fills were higher among PLWH vs. PLWoH (11.9 [10.1] vs. 9.2 [9.4]; < .001). CONCLUSIONS: Multimorbidity and polypharmacy were more prevalent among PLWH vs. matched PLWoH. Findings support the need to consider comorbidities and comedications when choosing ART and to minimize drug-drug interactions and adverse events to improve patient outcomes.
目的:描述艾滋病毒感染者(PLWH)与未感染艾滋病毒者(PLWoH)的合并症和合并用药负担。
方法:这是一项使用管理索赔数据进行的病例对照研究。通过抗逆转录病毒疗法(ART)的索赔或艾滋病毒/艾滋病诊断代码,于 2018 年 1 月 1 日至 12 月 31 日(索引日期由最早的索赔确定)期间确定成年 PLWH。在索引前(基线)至少 12 个月和索引后(随访)至少 30 天需要连续入组。患者在基线或随访期间需要有≥1 次艾滋病毒诊断。仅接受艾滋病毒预防的患者被排除在外。PLWoH 按人口统计学特征与 PLWH 2:1 匹配。使用具有普通最小二乘回归或 Rao-Scott 检验稳健标准误差的 -检验比较研究结果。
结果:该研究纳入了 20256 名 PLWH 和 40512 名匹配的 PLWoH,平均年龄为 52 岁。PLWH 与 PLWoH 的平均(标准差)Charlson 合并症指数评分分别为 0.93(1.59)和 0.61(1.28)(均<0.001),且≥1 种合并症的比例更高(分别为 69.1%和 54.5%,均<0.001)。最常见的合并症包括高血压(33.9%和 32.2%,均<0.001)、高血脂(29.4%和 24.6%,均<0.001)、慢性肾脏病(13.6%和 9.4%,均<0.001)、抑郁(13.1%和 7.3%,均<0.001)和药物滥用(12.8%和 7.1%,均<0.001)。PLWH 的非 ART 处方填写平均值(标准差)高于 PLWoH(11.9[10.1]和 9.2[9.4];均<0.001)。
结论:PLWH 比匹配的 PLWoH 更常见多种合并症和多种药物治疗。这些发现支持在选择 ART 时考虑合并症和合并用药的必要性,并尽量减少药物相互作用和不良反应,以改善患者的治疗结果。
Curr Med Res Opin. 2022-8
HIV Res Clin Pract. 2024-12
Int J Environ Res Public Health. 2023-2-15
Afr J Prim Health Care Fam Med. 2025-6-23
Pharmacoecon Open. 2025-6-9
Clin Auton Res. 2025-5-10
Braz Oral Res. 2025-4-4
Expert Rev Clin Pharmacol. 2024-7
Infect Dis Ther. 2024-5